Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 8/20 | 0.50 |
| ▸ | CYP2A13 | Q16696 | 4/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13331431 | 1.00 | HIF1A (0.50) | HIF1ACYP2A13HCRTR1HCRTR2MMP1 | |
| SCHEMBL3346009 | 0.84 | CYP2A13 (0.52) | CYP2A13HCRTR1HCRTR2MMP1MMP9 | |
| SCHEMBL14051401 | 0.81 | CYP2A13 (0.50) | CYP2A13HCRTR1HCRTR2MMP1MMP9 | |
| SCHEMBL13331412 | 0.81 | CYP2A13 (0.52) | CYP2A13HCRTR1HCRTR2SMN1; SMN2 | |
| SCHEMBL5216465 | 0.81 | HCRTR1 (0.60) | CYP2A13HCRTR1HCRTR2MMP1MMP9 | |
| SCHEMBL13361071 | 0.80 | CYP2A13 (0.48) | CYP2A13HCRTR1HCRTR2MMP1MMP9 | |
| SCHEMBL9407302 | 0.78 | HIF1A (0.43) | HIF1ASMN1; SMN2 | |
| SCHEMBL9407297 | 0.78 | HIF1A (0.43) | HIF1ASMN1; SMN2 | |
| SCHEMBL26144809 | 0.78 | HIF1A (0.62) | HIF1A | |
| SCHEMBL7627809 | 0.78 | HIF1A (0.62) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113778-A1 | PROCESS FOR PREPARING O-CHLOROMETHYLPHENYLGLYOXYLIC ESTERS, IMPROVED PROCESS FOR PREPARING (E)-2-(2-CHLOROMETHYLPHENYL)-2-ALKOXIMINOACETIC ESTERS, AND NOVEL INTERMEDIATES FOR THEIR PREPARATION | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2010-05-06 | — | — | US | disclosed |
| EP-2134673-A1 | IMPROVED PROCESS FOR PREPARING O-CHLOROMETHYLPHENYLGLYOXYLIC ESTERS, IMPROVED PROCESS FOR PREPARING (E)-2-(2-CHLOROMETHYLPHENYL)-2-ALKOXIMINOACETIC ESTERS, AND NOVEL INTERMEDIATES FOR THEIR PREPARATION | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2009-12-23 | — | — | EP | disclosed |
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| EP-1988900-A2 | PYRIDINE, PYRIMIDINE AND PYRAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008125592-A1 | IMPROVED PROCESS FOR PREPARING O-CHLOROMETHYLPHENYLGLYOXYLIC ESTERS, IMPROVED PROCESS FOR PREPARING (E)-2-(2-CHLOROMETHYLPHENYL)-2-ALKOXIMINOACETIC ESTERS, AND NOVEL INTERMEDIATES FOR THEIR PREPARATION | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2008-10-23 | — | — | WO | disclosed |
| WO-2007100610-A2 | PYRIDINE, PYRIMIDINE AND PYRAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113778-A1 | PROCESS FOR PREPARING O-CHLOROMETHYLPHENYLGLYOXYLIC ESTERS, IMPROVED PROCESS FOR PREPARING (E)-2-(2-CHLOROMETHYLPHENYL)-2-ALKOXIMINOACETIC ESTERS, AND NOVEL INTERMEDIATES FOR THEIR PREPARATION | CYP4F12, GRHPR, CYP4F2 | HIF1A 2680/4885CYP2A13 113/4885HCRTR1 4243/4885 |
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | CXCR3, CXCR1, CXCR5 | HIF1A 2265/4885CYP2A13 2502/4885HCRTR1 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.